This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular system in the initial report submitted to the fda on january 29, 2016.Conclusions code: unable to confirm complaint.The actual samples were not provided for evaluation, nor was any documentation in reference to the order placed or shipment received; therefore, the complaint was not confirmed.A review of the device history records revealed no issues that would indicate the improper product was packaged and shipped.A definitive root cause could not be determined.All available information has been placed on file in quality management for appropriate tracking, trending and follow up.
|